Convalescent Plasma Reduces Mortality and Decreases Hospitalization Stay in Patients with Moderate COVID-19 Pneumonia
Humans infected with SARS-CoV-2 may develop COVID-19, which manifests across a wide spectrum of clinical severity ranging from mild upper respiratory tract illnesses to diffuse viral pneumonia, causing acute respiratory failure. Many therapies have been tested for their efficacy in treating COVID-19...
Enregistré dans:
Auteurs principaux: | Maamoun Basheer, Elias Saad, Dorin Shlezinger, Nimer Assy |
---|---|
Format: | article |
Langue: | EN |
Publié: |
MDPI AG
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/39c341d34bd845b8a70eddb50ac35c47 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Convalescent Plasma for the Treatment of Severe COVID-19
par: Franchini M, et autres
Publié: (2021) -
Effectiveness of convalescent plasma therapy in eight non-intubated coronavirus disease 2019 patients in Indonesia: a case series
par: Theresia Monica Rahardjo, et autres
Publié: (2021) -
Convalescent plasma therapy in patients with coronavirus disease-19 – One year after: A brief review
par: Mariela Irabien-Zúñiga, et autres
Publié: (2021) -
SEIR Mathematical Model of Convalescent Plasma Transfusion to Reduce COVID-19 Disease Transmission
par: Hennie Husniah, et autres
Publié: (2021) -
Convalescent plasma therapy in an immunocompromised patient with multiple COVID‐19 flares: a case report
par: Frini Karaolidou, et autres
Publié: (2021)